Company Name: Nabriva Therapeutics AG

Nabriva Therapeutics AG is a biopharmaceutical company. The company focuses on the pleuromutilin class of antibiotics to develop anti-infectives designed to treat bacterial infections. The company’s lead product candidate is designed to treat moderate to severe community acquired bacterial pneumonia.

Ticker Symbol: NBRV (NASDAQ)

Company Website: www.nabriva.com

Social Media: Nabriva Therapeutics LinkedIn

Headquarters: Vienna, Austria